After report, FTC to sue PBMs
On Tuesday, the Federal Trade Commission released a scathing, two-years-in-the-making report about PBMs.
On Tuesday, the Federal Trade Commission released a scathing, two-years-in-the-making report about PBMs.
Several members have contacted us about a story that ran on NPR’s Morning Edition about a pharmacy in Texas that compounded the chemical used for lethal injections.
We’ve been bugging the California Board of Pharmacy (politely!) for a while, trying to get a statement on its position and enforcement posture regarding the compounding of FDA-approved drugs that are currently in shortage.
The Mamas and the Papas said you can’t trust Mondays, but that’s not always true. You can count on two things happening today, July 15. Whether you take advantage of them is up to you — but I hope you do.
APC has just released the 2023–2024 edition of our Compounding Pharmacy Snapshot — a slick overview of the practice of pharmacy compounding in the US of A.
Take our July 15 session (really, you should take it) where APC’s Tenille Davis is covering two of today’s critical topics: Best practices in both ketamine and GLP-1 compounding.
Registration is open for Compounders on Capitol Hill! If you’re planning to attend, the sooner you register the better because we’re starting to schedule visits with legislators, and we want to be sure you’re included.
APC CEO Scott Brunner and PCCA’s A.J. Day attended a forum in Washington, D.C., on the emergence of ketamine as an area of therapeutic interest.
APC is always keeping track of what state boards of pharmacy are up to, and we’ll reach out when we think something needs clarification. Here’s a sampling of the kind of letters we’ve sent recently.
We blasted through our expectations for our virtual town hall on compounding semaglutide on June 26, with almost 700 people registered.